Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Faldaprevir And Simeprevir Outshine Today’s Protease Inhibitors

Executive Summary

Phase III data for once-daily protease inhibitors demonstrate advantages over the currently approved candidates in the class, which are given three times daily. But in the rapidly changing and highly competitive hepatitis C market, just where these next-generation drugs might fit in remains unclear.

You may also be interested in...



Janssen Files Once-Daily Proteasome Inhibitor; Other New Drug News, In Brief

Boehringer Ingelheim submits type 2 diabetes therapy empagliflozin; Pozen seeks a partner to help it commercialize its aspirin/PPI combo following its NDA submission; Eisai gets FDA approval for pediatric use of acid reflux drug Aciphex; Merck announces FDA’s acceptance of its oral grass pollen allergy immunotherapy BLA; the EMA accepts Shionogi’s menopause drug Osphena for review, and IntelGenx submits an NDA for an oral film version of Maxalt-MLT.

Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities

For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel